Downloading...
Download

Clinical

$LCTX biotech company analysis *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share. My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20. ORIGINAL ENTRY: $2.23 AVERAGING UP AT: $2.70 TAKE PROFIT: $4.20 STOP PROFIT LOSS: $2.50 If you want to see more, please like and follow us @SimplyShowMeTheMoney
AMEX:LCTXLong
by SimplyShowMeTheMoney
Nordic Nanovector to make a new attempt at breaking downtrend?Technicals: Nordic Nanovector retraced from recent high to fill gaps down to support at NOK 48, which triggered a strong reversal pattern. Investors will be keen to follow if the stock establishes a trading range above 53 NOK which would represent a breakout from the recent downtrend, and even more if the stock could possibly break free from the almost two year long main downtrend from ATH in december 2016. Fundamentals: Reversal could be helped by this weeks news that Nordic Nanovector will be presenting three posters at this years ASH conference. nanoinvestors.wordpress.com At the same time Jefferies Financial group published a BUY recommendation for $NANO.OL with target price 115 NOK, representing a more than 100% upside from todays level. nanoinvestors.wordpress.com Nordic Nanovector was also mentioned as a possible target of M&A interest by nordic brokerage ABG Sundal Collier nanoinvestors.wordpress.com
NLong
by savepiginvest
$AITB - AIT Therapeutics Inc - Buy AlertAIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
ALong
by TradeForProfits
$CTRV Runway Is Cleared for Take-Off$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to move a stock and takes care of his shareholders while at the same time taking care of the company and business. Not to mention 3 drug candidates in clinical trials. Liking what I'm seeing here.
CLong
by StockGuild